Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Lilly offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash, an aggregate of up to approximately $1.3 billion).

The transaction is expected to close in the third quarter of 2025. The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve’s common stock ended on June 16, 2025, the last trading day before the deal announcement.

Also Read: Sarepta ...